Categorical Language Fluency Smartphone Application
Device4 weeks' training
NCT Number: NCT02848404
The purpose of this study is to examine therapeutic efficacy of categorical language fluency smartphone game application in mild cognitive impairment and mild Alzheimer's dementia.
Looking for future studies?
Notify Me55 year and older
All sexes
Interventional
Not applicable
The Categorical Language Fluency Smartphone Game Application was developed based on the semantic distance training, which was effective in improving categorical language fluency of mild cognitive impairment and mild Alzheimer's dementia. 10 patients with mild cognitive impairment and another 10 patients with mild Alzheimer's dementia were recruited to examine therapeutic efficacy of the application.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
4 weeks' training
Time frame: 4-weeks treatment
Log to assess compliance of participant(by describing frequency and duration of training by using application)
Time frame: after 4-weeks treatment
to evaluate efficacy of application
Time frame: after 4-weeks treatment
to evaluate efficacy of application
Time frame: after 4-weeks treatment
to evaluate efficacy of application
Seoul National University Bundang Hospital
Other
A Study of Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application in Mild Cognitive Impairment and Mild Alzheimer's Dementia (Baseline Study)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04073628
Alzheimer Disease, Alzheimer's Disease
Albany, New York, United States
View Trial DetailsNCT00647478
Alzheimer Disease, Alzheimer's Disease
Paris, France
View Trial DetailsNCT06595030
Alzheimer Disease, Alzheimer's Disease
Menands, New York, United States
View Trial DetailsNCT04426539
Alzheimer Disease, Alzheimer's Disease
Philadelphia, Pennsylvania, United States
View Trial Details